Hexahydro-pyrrolo-isoquinoline compounds

Abstract

Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H 3 receptor and serotonin transporter modulators useful in the treatment of histamine H 3 receptor- and serotonin-mediated diseases.

1 . A compound of formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         n is 0 or 1; 
         m is 0, 1, or 2; 
         R 2  and R 3  are independently selected from —H, or from the group consisting of: 
         A) —C 1-6 alkyl, —C 3-6 alkenyl, —C 3-6 alkynyl, —C 3-7 cycloalkyl, —C 1-6 alkylC 3-7 cycloalkyl, benzyl; 
         B) phenyl or pyridyl, optionally fused at two adjacent carbon ring members to a three- or four-membered hydrocarbon moiety to form a fused five- or six-membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), and which moiety has up to one additional carbon atom optionally replaced by —N═; 
         C) a 4-8 membered heterocyclic ring, said heterocyclic ring having a carbon atom which is the point of attachment, having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , and >NH, and having 0 or 1 double bonds; and 
         D) a monocyclic aromatic hydrocarbon group having five or six ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), having up to one additional carbon atom optionally replaced by —N═, and optionally benzofused or pyridofused; 
         where each of A)-D) is optionally mono-, di-, or tri-substituted with a moiety selected from the group consisting of —OH, —C 1-4 alkylOH, —OC 1-6 alkyl, —CN, —NO 2 , —N(Rd)R e  (wherein R d  and R e  are independently —H or —C 1-6 alkyl), —C(O)N(Rd)R e , —N(R)C(O)Rd, —N(Rd)SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(Rd)R e , —SCF 3 , halo, —CF 3 , —OCF 3 , —COOH, —COOC 1-6 alkyl, —OC(O)N(Rd)R e , and —OC(O)OR d ; 
         or, alternatively, 
         R 2  and R 3  may be taken together with the nitrogen to which they are attached to form a 4-8 membered heterocyclic ring, said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from >O, >S(O) 0-2 , >NH, and >NR f , having 0 or 1 double bonds, having 0, 1, or 2 carbon members separated from the nitrogen of attachment by at least one carbon member which is a carbonyl, optionally benzo or pyrido fused, optionally having one carbon member that forms a bridge, and having 0-5 carbon member substituents R ff ,
 R f  is selected from the group consisting of —C 1-6 alkyl optionally mono-, di-, or tri-substituted with halo, —C 3-6 alkenyl, —C 3-6 alkynyl, —C 3-7 cycloalkyl, —C 1-6 alkylC 3-7 cycloalkyl, —C 2-6 alkylOH, —C(O)N(R g )R h  (wherein R g  and R h  are independently —H or —C 1-6 alkyl), —C(O)R i  (where R i  is —C 1-6 alkyl, —C 3-8 cycloalkyl, phenyl, or 5- or 6-membered aromatic heterocyclyl, each optionally mono-, di-, or tri-substituted with —C 1-3 alkyl, —OH, —OC 1-6 alkyl, —CF 3 , or halo), —S(O) 0-2 —C 1-6 alkyl, and —COOC 1-6 alkyl; 
 R ff  is selected from the group consisting of —C 1-6 alkyl optionally mono-, di-, or tri-substituted with halo, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 3-7 cycloalkyl, —C 1-6 alkylC 3-7 cycloalkyl, halo, —OH, —C 1-6 alkylOH, —OC 1-6 alkyl, —OC 2-3 alkylO—, —CN, —NO 2 , —N(R g )R h  (wherein R g  and R h  are independently —H or —C 1-6 alkyl), —C(O)N(R g )R h , —N(R g )C(O)R g , —N(R g )SO 2 C 1-6 alkyl, —C(O)R i  (where R i  is —C 1-6 alkyl, —C 3-8 cycloalkyl, phenyl, or 5- or 6-membered aromatic heterocyclyl, each optionally mono-, di-, or tri-substituted with —C 1-3 alkyl, —OH, —OC 1-6 alkyl, —CF 3 , or halo), —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R y )R z , —SCF 3 , —OCF 3 , —COOH, and —COOC 1-6 alkyl; 
 
         R 4  is —OH, —OC 1-6 alkyl, —CF 3 , —C 1-6 alkyl, or halo; two R 4  substituents may be taken together to form methylene or ethylene; or one of R 4  is taken together with R 2  to form methylene, ethylene, or propylene; wherein each methylene, ethylene, or propylene is optionally substituted with —OH, —OC 1-6 alkyl, —SC 1-6 alkyl, —CF 3 , —C 1-6 alkyl, amino, or halo; 
         R 5  is selected from the group consisting of —H, —C 1-6 alkyl, —OH, —OC 1-6 alkyl, —SC 1-6 alkyl, and halo; 
         Ar 1  is an aryl or heteroaryl ring selected from the group consisting of:
 a) phenyl, optionally mono-, di-, or tri-substituted with RJ or di-substituted on adjacent carbons with —OC 1-4 alkyleneO— optionally mono- or di-substituted with fluoro, —(CH 2 ) 2-3 NH—, —(CH 2 ) 1-2 NH(CH 2 )—, —(CH 2 ) 2-3 N(C 1-4 alkyl)-, or —(CH 2 ) 1-2 N(C 1-4 alkyl)(CH 2 )—; 
 R j  is selected from the group consisting of
 1) —OH, —C 1-6 alkyl, —OC 1-6 alkyl optionally mono-, di-, or tri-substituted with halo, —C 2-6 alkenyl, —OC 3-6 alkenyl, —C 2-6 alkynyl, —OC 3-6 alkynyl, —C 3-6 cycloalkyl, —OC 3-6 cycloalkyl, —CN, —NO 2 , —N(R k )R l  (wherein R k  and R l  are independently —H or —C 1-6 alkyl), —N(R k )COR l , —N(R k )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —C(O)N(R m )R n  (wherein R m  and R n  are independently —H or —C 1-6 alkyl, or R m  and R n  taken together with their nitrogen of attachment form a 4-8 membered heterocyclic ring having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , >NH, and >NC 1-6 alkyl, having 0 or 1 double bonds, having 0 or 1 carbonyl members), —SO 2 N(R m )R n , —SCF 3 , halo, —CF 3 , —COOH, —COOC 1-6 alkyl, and —COOC 3-7 cycloalkyl; and 
 2) a 4-8 membered saturated or partially saturated heterocyclic ring, having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , >NH, and >NC 1-6 alkyl, having 0 or 1 carbonyl members; said ring optionally mono-, di-, or tri-substituted with RP;
 R p  is a substituent independently selected from the group consisting of: —OH, —C 1-6 alkyl, —OC 1-6 alkyl, phenyl, —CN, —NO 2 , —N(R q )R r  (wherein R q  and R r  are independently —H, —C 1-6 alkyl, or —C 2-6 alkenyl), —C(O)N(R q )R r , —N(R q )C(O)R r , —N(R q )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R q )R r , —SCF 3 , halo, —CF 3 , —OCF 3 , —OCHF 2 , —COOH, and —COOC 1-6 alkyl; 
 
 
 b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N═, the fused rings optionally mono-, di-, or tri-substituted with R t ;
 R t  is a substituent independently selected from the group consisting of: —OH, —C 1-6 alkyl, —OC 1-6 alkyl, phenyl, —CN, —NO 2 , —N(R u )R v  (wherein R u  and R v  are independently —H or —C 1-6 alkyl), —C(O)N(R u )R v , —N(R u )C(O)R v , —N(R u )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R u )R v , —SCF 3 , halo, —CF 3 , —OCF 3 , —OCHF 2 , —COOH, and —COOC 1-6 alkyl; 
 
 c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has 0, 1, or 2 carbon atoms replaced by —N═, the fused rings optionally mono-, di-, or tri-substituted with R t ; 
 d) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), having up to one additional carbon atom optionally replaced by —N═, optionally mono- or di-substituted with R t , and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R t ; and 
 e) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N═, optionally mono- or di-substituted with R t , and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R t ; 
 
         and enantiomers, diastereomers, hydrates, solvates thereof, and pharmaceutically acceptable salts, esters and amides thereof. 
       
     
     
         2 . The compound of  claim 1  wherein n is 0 or 1. 
     
     
         3 . The compound of  claim 1  wherein m is 0. 
     
     
         4 . The compound of  claim 1  wherein R 2  and R 3  are independently selected from —H, or optionally substituted, from the group consisting of:
 A) methyl, ethyl, isopropyl, butyl, pentyl, hexyl, allyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, benzyl, 
 B) phenyl, pyridyl, 4-, 5-, 6- or 7-benzoxazolyl, 4-, 5-, 6- or 7-benzothiophenyl, 4-, 5-, 6- or 7-benzofuranyl, 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6- or 7-benzthiazolyl, 4-, 5-, 6- or 7-benzimidazolyl, 4-, 5-, 6- or 7-indazolyl, imidazo[1,2-a]pyridin-5,6,7 or 8-yl, pyrazolo[1,5-a]pyridin-4,5,6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-yl, 
 C) azetidinyl, pyrrolidinyl, piperidinyl, and 
 D) furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 3-indoxazinyl, 2-benzoxazolyl, 2- or 3-benzothiophenyl, 2- or 3-benzofuranyl, 2- or 3-indolyl, 2-benzthiazolyl, 2-benzimidazolyl, and 3-indazolyl. 
 
     
     
         5 . The compound of  claim 1  wherein R 2  and R 3 , optionally substituted, are independently selected from methyl, ethyl, isopropyl, pyrrolidinyl, piperidinyl, 2-benzothiazolyl, and methoxyethyl. 
     
     
         6 . The compound of  claim 1  wherein R 2  and R 3  are, independently, ethyl, isopropyl, methoxyethyl, or 2-benzothiazolyl. 
     
     
         7 . The compound of  claim 1  wherein R 2  and R 3 , optionally substituted, are taken together with the nitrogen to which they are attached to form a ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, homopiperidinyl, 1,3-dihydro-isoindol-2-yl, 5,6-dihydro-4H-pyrimidin-1-yl, and 1,1-dioxo-1λ 6 -thiomorpholin-4-yl. 
     
     
         8 . The compound of  claim 1  wherein R 2  and R 3  are taken together with the nitrogen to which they are attached to form a 4-8 membered heterocyclic ring, said heterocyclic ring selected from piperidine, pyrrolidine, and morpholine, said ring substituted with 1 or 2 substituents R ff . 
     
     
         9 . The compound of  claim 1  wherein R ff  is selected from the group consisting of methyl, ethyl, isopropyl, butyl, hexyl, —CF 3 , —CHF 2 , vinyl, allyl, propargyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylethyl, bromo, chloro, fluoro, iodo, —OH, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, isopropoxy, pentyloxy, —O(CH 2 ) 2 O—, —O(CH 2 ) 3 O—, —CN, amino, methylamino, dimethylamino, diethylamino, diethylcarbamoyl, methanesulfanyl, methanesulfonyl, methanesulfonamido, —C(O)R i , —COOH, and ethoxycarbonyl. 
     
     
         10 . The compound of  claim 1  wherein R ff  is selected from the group consisting of methyl, fluoro, —OH, —CF 3 , hydroxymethyl, hydroxyethyl, dimethylamino, ethoxycarbonyl, and —O(CH 2 ) 2 O—. 
     
     
         11 . The compound of  claim 1  wherein R i  is selected from the group consisting of methyl, pyridyl, isopropyl, cyclobutyl, cyclopropyl, N-methylpyrrolyl, and 1-methylimidazolyl. 
     
     
         12 . The compound of  claim 1  wherein R 2  and R 3  are taken together with the nitrogen to which they are attached to form azetidinyl, 2-methylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3-dimethylaminopyrrolidinyl, 2,5-dimethylpyrrolidinyl, 2-trifluoromethylpyrrolidinyl, 2-hydroxymethylpyrrolidinyl, piperidinyl, 4-fluoropiperidinyl, 3,3-difluoropiperidinyl, 4,4-difluoropiperidinyl, 3-trifluoromethylpiperidinyl, 4-trifluoromethylpiperidinyl, 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, morpholinyl, 4-cyanopiperidinyl, 4-carboethoxypiperidinyl, 3-hydroxypiperidinyl, 4-hydroxypiperidinyl, 2-hydroxymethylpiperidinyl, 3-hydroxymethylpiperidinyl, 4-hydroxymethylpiperidinyl, 4-hydroxyethylpiperidinyl, 3-methylmorpholin-4-yl, 3-hydroxymethylmorpholin-4-yl, 2-hydroxymethylmorpholin-4-yl, 2,6-dimethylmorpholin-4-yl, 1,3-dihydro-isoindol-2-yl, 5,6-dihydro-4H-pyrimidin-1-yl, 1,1-dioxo-1λ 6 -thiomorpholin-4-yl, or 2-methylmorpholin-4-yl. 
     
     
         13 . The compound of  claim 1  wherein R 2  and R 3  are taken together with the nitrogen to which they are attached to form 4-fluoropiperidinyl, morpholinyl, or 3-methylmorpholin-4-yl. 
     
     
         14 . The compound of  claim 1  wherein R 4  is methoxy, ethoxy, isopropoxy, pentyloxy, —CF 3 , methyl, ethyl, propyl, isobutyl, pentyl, chloro, or fluoro. 
     
     
         15 . The compound of  claim 1  wherein R 4  is hydroxy, methyl, methoxy, fluoro, or —CF 3 . 
     
     
         16 . The compound of  claim 1  wherein two R 4  are taken together to form methylene. 
     
     
         17 . The compound of  claim 1  wherein R 2  and one of R 4  are taken together form methylene, ethylene, or propylene, each optionally substituted with —OH, —OC 1-6 alkyl, —SC 1-6 alkyl, —CF 3 , —C 1-6 alkyl, amino, or halo. 
     
     
         18 . The compound of  claim 1  wherein R 2  and one of R 4  are taken together to form methylene or ethylene. 
     
     
         19 . The compound of  claim 1  wherein R 5  is hydrogen, methyl, ethyl, isopropyl, hexyl, hydroxyl, methoxy, ethoxy, isopropoxy, methylsulfanyl, bromo, chloro, fluoro, or iodo. 
     
     
         20 . The compound of  claim 1  wherein R 5  is hydrogen. 
     
     
         21 . The compound of  claim 1  wherein Ar 1 , optionally substituted, is selected from the group consisting of:
 a) phenyl, 5-, 6-, 7-, 8-benzo-1,4-dioxanyl, 4-, 5-, 6-, 7-benzo-1,3-dioxolyl, 4-, 5-, 6-, 7-indolinyl, 4-, 5-, 6-, 7-isoindolinyl, 1,2,3,4-tetrahydro-quinolin-4,5,6 or 7-yl, 1,2,3,4-tetrahydro-isoquinolin-4,5,6 or 7-yl, 
 b) 4-, 5-, 6- or 7-benzoxazolyl, 4-, 5-, 6- or 7-benzothiophenyl, 4-, 5-, 6- or 7-benzofuranyl, 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6- or 7-benzthiazolyl, 4-, 5-, 6- or 7-benzimidazolyl, 4-, 5-, 6- or 7-indazolyl, imidazo[1,2-a]pyridin-5,6,7 or 8-yl, pyrazolo[1,5-a]pyridin-4,5,6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-yl, 
 c) naphthyl, 5-, 6-, 7- or 8-isoquinolinyl, 5-, 6-, 7- or 8-quinolinyl, 5-, 6-, 7- or 8-quinoxalinyl, 5-, 6-, 7- or 8-quinazolinyl, 
 d) furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 3-indoxazinyl, 2-benzoxazolyl, 2- or 3-benzothiophenyl, 2- or 3-benzofuranyl, 2- or 3-indolyl, 2-benzthiazolyl, 2-benzimidazolyl, 3-indazolyl, and 
 e) pyridinyl, pyridinyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, 1-, 3- or 4-isoquinolinyl, 2-, 3- or 4-quinolinyl, 2- or 3-quinoxalinyl, 2- or 4-quinazolinyl, [1,5], [1,6], [1,7], or [1,8]naphthyridin-2-, 3-, or 4-yl, [2,5], [2,6], [2,7], [2,8]naphthyridin-1-, 3-, or 4-yl. 
 
     
     
         22 . The compound of  claim 1  wherein Ar 1 , optionally substituted, is selected from the group consisting of phenyl, pyridyl, pyrazinyl, thiazolyl, pyrazolyl, and thiophenyl. 
     
     
         23 . The compound of  claim 1  wherein Ar 1  is selected from the group consisting of phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-ethylphenyl, 3-ethynylphenyl, 4-ethynylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3-iodophenyl, 4-iodophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 4-difluoromethoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 3-acetylphenyl, 4-acetylphenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-methoxyphenyl, 3-chloro-4-difluoromethoxyphenyl, 3-fluoro-4-chlorophenyl, benzo[1,3]dioxol-4 or 5-yl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-hydroxy-2-methylphenyl, 4-hydroxy-3-fluorophenyl, 3,4-dihydroxyphenyl, 4-aminophenyl, 4-dimethylaminophenyl, 4-carbamoylphenyl, 4-fluoro-3-methylphenyl, 4-methanesulfanylphenyl, 4-methanesulfinylphenyl, 4-methanesulfonylphenyl, 4-trifluoromethanesulfanylphenyl, thiophen-2-yl, thiophen-3-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-chloro-5-pyridinyl, 2-dimethylamino-5-pyridinyl, 2-methoxy-5-pyridinyl, 2-thiomethyl-5-pyridinyl, 2-hydroxy-5-pyridinyl, oxazol-5-yl, thiazol-5-yl, thiazol-2-yl, 2H-pyrazol-3-yl, pyrazin-2-yl, 1-naphthyl, 2-naphthyl, 4-imidazol-1-ylphenyl, 4-pyrazol-1-ylphenyl, 1H-indol-5-yl, 1H-benzimidazol-5-yl, benzo[b]thiophen-7-yl, and 4-biphenyl. 
     
     
         24 . The compound of  claim 1  wherein Ar 1 , optionally substituted with halo, is 4-methoxyphenyl or 4-methanesulfanylphenyl. 
     
     
         25 . The compound of  claim 1  wherein Ar 1  is cis to the pyrrolidine ring of formula (I). 
     
     
         26 . The compound of  claim 1  wherein the R 3 R 2 N-containing ether substituent of formula (I) is at the 9-position. 
     
     
         27 . A compound selected from the group consisting of:
 Cis-6-Phenyl-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1a]isoquinoline;   Trans-6-Phenyl-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1a]isoquinoline;   Trans-6-Phenyl-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1a]isoquinoline;   Cis-6-(4-Nitro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Nitro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Nitro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-4-[9-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-phenylamine;   Cis-6-(3-Nitro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3-Nitro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3-nitro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3-nitro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidine-1-yl-propoxy)-6-p-tolyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-9-(3-Piperidine-1-yl-propoxy)-6-p-tolyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-7-(3-Piperidine-1-yl-propoxy)-6-p-tolyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3,4-Dichloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3,4-Dichloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3,4-Dichloro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-(4-trifluoromethyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-9-(3-Piperidin-1-yl-propoxy)-6-(4-trifluoromethyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-7-(3-Piperidin-1-yl-propoxy)-6-(4-trifluoromethyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   1S,6R-6-(4-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   1R,6S-6-(4-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Methoxy-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Methoxy-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-4-[9-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-phenol;   Trans-4-[7-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-phenol;   Cis-6-(3-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3-Methoxy-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3-Chloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3-Chloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(3-Chloro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(2-Chloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(2-Chloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(2-Chloro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(2-Chloro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(2-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(2-Methoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Fluoro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Fluoro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Fluoro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-3-[9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-phenol;   Cis-2-[9-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-phenol;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-(4-trifluoromethoxy-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3,4-Dimethoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(2,4-Dimethoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(2,5-dimethoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3,5-Dimethoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3,4,5-Trimethoxy-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-thiophen-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-thiophen-3-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-9-(3-piperidin-1-yl-propoxy)-6-thiophen-3-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-pyridin-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-pyridin-3-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-pyridin-4-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-9-(3-Piperidin-1-yl-propoxy)-6-pyridin-4-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-7-(1-Isopropyl-piperidin-4-yloxy)-4-(4-methoxy-phenyl)-2-methyl-1,2,3,4-tetrahydro-isoquinoline;   Cis-9-(1-Isopropyl-piperidin-4-ylmethoxy)-6-(4-methoxy-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-Dimethyl-{4-[9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-phenyl}-amine;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-m-tolyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3-Iodo-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-(3-trimethylsilanylethynyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3-Ethynyl-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Iodo-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Iodo-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-(4-trimethylsilanylethynyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Ethynyl-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Methylsulfanyl-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Methylsulfanyl-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(4-Methylsulfanyl-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Bromo-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-4-[9-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-benzonitrile;   Trans-4-[9-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-benzonitrile;   Trans-6-(4-Bromo-phenyl)-8-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-4-[8-(3-Piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-benzonitrile;   Trans-6-Phenyl-8-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-Phenyl-8-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Methoxy-phenyl)-9-[3-(3S-methyl-morpholin-4-yl)-propoxy]-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-[3-(4-Fluoro-piperidin-1-yl)-propoxy]-6-(4-methoxy-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-imidazol-1-yl-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Imidazol-1-yl-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-(4-pyrazol-1-yl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-pyrazin-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-9-(3-Morpholin-4-yl-propoxy)-6-pyrazin-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-5-[9-(3-Morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-pyridin-2-ol;   Trans-5-[9-(3-Morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-pyridin-2-ol;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-thiazol-5-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-thiazol-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-(2H-pyrazol-3-yl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-Imidazo[1,2-a]pyridin-3-yl-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-thiophen-3-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-thiophen-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-3-[9-(3-Morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-benzonitrile;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-pyridin-3-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-pyridin-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-(4-trifluoromethylsulfanyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Morpholin-4-yl-propoxy)-6-(3-trifluoromethylsulfanyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Methylsulfanyl-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3-Chloro-4-methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(3-Fluoro-4-methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-Chloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Chloro-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-9-(3-Piperidin-1-yl-propoxy)-6-(3-trifluoromethyl-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-Biphenyl-4-yl-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   9-(3-Morpholin-4-yl-propoxy)-6-naphthalen-2-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   9-(3-Morpholin-4-yl-propoxy)-6-quinolin-7-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(1H-Indol-5-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(1H-Benzoimidazol-5-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(1H-Benzoimidazol-2-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(1-Methyl-1H-benzoimidazol-2-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   9-(3-Morpholin-4-yl-propoxy)-6-naphthalen-1-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-Benzo[b]thiophen-7-yl-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(6-Chloro-pyridin-3-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Dimethyl-{5-[9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-6-yl]-pyridin-2-yl}-amine;   6-(6-Methoxy-pyridin-3-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   9-(3-Morpholin-4-yl-propoxy)-6-oxazol-5-yl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(1H-Imidazol-2-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(1-Methyl-1H-imidazol-2-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(3H-Imidazol-4-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(3-Methyl-3H-imidazol-4-yl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   6-(3-Chloro-4-Difluoromethoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   (4-{3-[6-(4-Methoxy-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-9-yloxy]-propyl}-morpholin-2-yl)-methanol;   (4-{3-[6-(4-Methoxy-phenyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinolin-9-yloxy]-propyl}-morpholin-3-yl)-methanol; and   6-(3,5-Bis-trifluoromethyl-phenyl)-9-(3-piperidin-1-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline.   
     
     
         28 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one compound of formula (I). 
     
     
         29 . A method for the treatment or prevention of a CNS disorder selected from the group consisting of: sleep/wake and arousal/vigilance disorders, insomnia, jet lag, disturbed sleep, attention deficit hyperactivity disorders (ADHD), attention-deficit disorders, learning and memory disorders, learning impairment, memory impairment, memory loss, cognitive dysfunction, migraine, neurogenic inflammation, dementia, mild cognitive impairment, pre-dementia, Alzheimer's disease, epilepsy, narcolepsy with or without associated cataplexy, cataplexy, disorders of sleep/wake homeostasis, idiopathic somnolence, excessive daytime sleepiness (EDS), circadian rhythm disorders, sleep/fatigue disorders, fatigue, drowsiness associated with sleep apnea, sleep impairment due to perimenopausal hormonal shifts, Parkinson's-related fatigue, MS-related fatigue, depression-related fatigue, chemotherapy-induced fatigue, work-related fatigue, lethargy, eating disorders, obesity, motion sickness, vertigo, schizophrenia, substance abuse, bipolar disorders, manic disorders and depression in mammals, comprising the step of administering to a mammal suffering therefrom an effective amount of at least one compound of formula (I). 
     
     
         30 . A method according to  claim 29 , further comprising administering one or more therapeutic agents selected from the group consisting of H 1  receptor antagonists, H 2  receptor antagonists, H 3  receptor antagonists, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, non-selective serotonin re-uptake inhibitors, acetylcholinesterase inhibitors, and modafinil. 
     
     
         31 . A method for the treatment or prevention of a CNS disorder selected from the group consisting of: depression, disturbed sleep, fatigue, lethargy, cognitive impairment, memory impairment, memory loss, learning impairment, and attention-deficit disorders in mammals, comprising the step of administering to a mammal suffering therefrom an effective amount of at least one compound of formula (I). 
     
     
         32 . A compound of  claim 1  isotopically-labelled to be detectable by PET or SPECT. 
     
     
         33 . A method for studying disorders mediated by the histamine H 3  receptor and the serotonin transporter comprising the step of using an  18 F-labeled or  11 C-labelled compound of formula (I) as a positron emission tomography (PET) molecular probe. 
     
     
         34 . A method for the treatment or prevention of a disease selected from the group consisting of: depression, disturbed sleep, fatigue, lethargy, cognitive impairment, memory impairment, memory loss, learning impairment, and attention-deficit disorders in mammals, comprising the step of administering to a mammal suffering therefrom an effective amount of a compound having both H 3  receptor modulating activity and serotonin transporter modulating activity. 
     
     
         35 . The method of  claim 34 , wherein the H 3  receptor binding activity is at least 20 nM in the human H 3  binding assay. 
     
     
         36 . The method of  claim 34 , wherein the serotonin transporter binding activity is at least 20 nM in the human SERT binding assay. 
     
     
         37 . The method of  claim 34 , wherein the ratio of the H 3  receptor binding activity in the human H 3  binding assay and the serotonin transporter binding activity in the human SERT binding assay is between 10:1 and 1:10. 
     
     
         38 . A compound selected from the group consisting of:
 (1R,6S)-6-(4-Methylsulfanyl-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   (1S,6R)-6-(4-Methylsulfanyl-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   (1S,6R)-6-(4-Methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   (1S,6S)-6-(4-Methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-Methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   (1R,6R)-6-(4-Methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline; and   (1S,6S)-6-(4-Methoxy-phenyl)-9-(3-morpholin-4-yl-propoxy)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline.   
     
     
         39 . A compound of formulae (II) or (III): 
       
         
           
           
               
               
           
         
         wherein 
         R 2  and R 3  are independently selected from —H, or from the group consisting of: 
         A) —C 1-6 alkyl, —C 3-6 alkenyl, —C 3-6 alkynyl, —C 3-7 cycloalkyl, —C 1-6 alkylC 3-7 cycloalkyl, benzyl; 
         B) phenyl or pyridyl, optionally fused at two adjacent carbon ring members to a three- or four-membered hydrocarbon moiety to form a fused five- or six-membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), and which moiety has up to one additional carbon atom optionally replaced by —N═; 
         C) a 4-8 membered heterocyclic ring, said heterocyclic ring having a carbon atom which is the point of attachment, having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , and >NH, and having 0 or 1 double bonds; and 
         D) a monocyclic aromatic hydrocarbon group having five or six ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), having up to one additional carbon atom optionally replaced by —N═, and optionally benzofused or pyridofused; 
         where each of A)-D) is optionally mono-, di-, or tri-substituted with a moiety selected from the group consisting of —OH, —C 1-4 alkylOH, —OC 1-6 alkyl, —CN, —NO 2 , —N(Rd)R e  (wherein Rd and R e  are independently —H or —C 1-6 alkyl), —C(O)N(Rd)R e , —N(Rd)C(O)Rd, —N(Rd)SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(Rd)R e , —SCF 3 , halo, —CF 3 , —OCF 3 , —COOH, —COOC 1-6 alkyl, —OC(O)N(Rd)R e , and —OC(O)OR d ; 
         or, alternatively, 
         R 2  and R 3  may be taken together with the nitrogen to which they are attached to form a 4-8 membered heterocyclic ring, said heterocyclic ring having 0 or 1 additional heteroatom members separated from the nitrogen of attachment by at least one carbon member and selected from >O, >S(O) 0-2 , >NH, and >NR f , having 0 or 1 double bonds, having 0, 1, or 2 carbon members separated from the nitrogen of attachment by at least one carbon member which is a carbonyl, optionally benzo or pyrido fused, optionally having one carbon member that forms a bridge, and having 0-5 carbon member substituents R ff ,
 R f  is selected from the group consisting of —C 1-6 alkyl optionally mono-, di-, or tri-substituted with halo, —C 3-6 alkenyl, —C 3-6 alkynyl, —C 3-7 cycloalkyl, —C 1-6 alkylC 3-7 cycloalkyl, —C 2-6 alkylOH, —C(O)N(R g )R h  (wherein R g  and R h  are independently —H or —C 1-6 alkyl), —C(O)R i  (where R i  is —C 1-6 alkyl, —C 3-8 cycloalkyl, phenyl, or 5- or 6-membered aromatic heterocyclyl, each optionally mono-, di-, or tri-substituted with —C 1-3 alkyl, —OH, —OC 1-6 alkyl, —CF 3 , or halo), —S(O) 0-2 —C 1-6 alkyl, and —COOC 1-6 alkyl; 
 R ff  is selected from the group consisting of —C 1-6 alkyl optionally mono-, di-, or tri-substituted with halo, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 3-7 cycloalkyl, —C 1-6 alkylC 3-7 cycloalkyl, halo, —OH, —C 1-6 alkylOH, —OC 2-3 alkylO—, —CN, —NO 2 , —N(R g )R h  (wherein R g  and R h  are independently —H or —C(O)N(R g )R h , —N(R g )C(O)R g , —N(R g )SO 2 C 1-6 alkyl, —C(O)R i  (where R i  is —C 1-6 alkyl, —C 3-8 cycloalkyl, phenyl, or 5- or 6-membered aromatic heterocyclyl, each optionally mono-, di-, or tri-substituted with —C 1-3 alkyl, —OH, —CF 3 , or halo), —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R y )R z , —SCF 3 , —OCF 3 , —COOH, and —COOC 1-6 alkyl; 
 
         R 5  is selected from the group consisting of —H, —OH, —OC 1-6 alkyl, —SC 1-6 alkyl, and halo; and 
         Ar 1  is an aryl or heteroaryl ring selected from the group consisting of:
 a) phenyl, optionally mono-, di-, or tri-substituted with W or di-substituted on adjacent carbons with —OC 1-4 alkyleneO— optionally mono- or di-substituted with fluoro, —(CH 2 ) 2-3 NH—, —(CH 2 ) 1-2 NH(CH 2 )—, —(CH 2 ) 2-3 N(C 1-4 alkyl)-, or —(CH 2 ) 1-2 N(C 1-4 alkyl)(CH 2 )—; 
 R j  is selected from the group consisting of
 1) —OH, —C 1-6 alkyl, —OC 1-6 alkyl optionally mono-, di-, or tri-substituted with halo, —C 2-6 alkenyl, —OC 3-6 alkenyl, —C 2-6 alkynyl, —OC 3-6 alkynyl, —C 3-6 cycloalkyl, —OC 3-6 cycloalkyl, —CN, —NO 2 , —N(R k )R l  (wherein R k  and R l  are independently —H or —C 1-6 alkyl), —N(R k )COR l , —N(R k )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —C(O)N(R m )R n  (wherein R m  and R n  are independently —H or —C 1-6 alkyl, or R m  and R n  taken together with their nitrogen of attachment form a 4-8 membered heterocyclic ring having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , >NH, and >NC 1-6 alkyl, having 0 or 1 double bonds, having 0 or 1 carbonyl members), —SO 2 N(R m )R n , —SCF 33  halo, —CF 33 —COOH, —COOC 1-6 alkyl, and —COOC 3-7 cycloalkyl; and 
 2) a 4-8 membered saturated or partially saturated heterocyclic ring, having 1 or 2 heteroatom members selected from >O, >S(O) 0-2 , >NH, and >NC 1-6 alkyl, having 0 or 1 carbonyl members; said ring optionally mono-, di-, or tri-substituted with R p ;
 R p  is a substituent independently selected from the group consisting of: —OH, —C 1-6 alkyl, —OC 1-6 alkyl, phenyl, —CN, —NO 2 , —N(R q )R r  (wherein R q  and R r  are independently —H, —C 1-6 alkyl, or —C 2-6 alkenyl), —C(O)N(R q )R r , —N(R q )C(O)R r , —N(R q )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R q )R r , —SCF 33  halo, —CF 3 , —OCF 3 , —OCHF 2 , —COOH, and —COOC 1-6 alkyl; 
 
 
 b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N═, the fused rings optionally mono-, di-, or tri-substituted with R t ;
 R t  is a substituent independently selected from the group consisting of: —OH, —C 1-6 alkyl, —OC 1-6 alkyl, phenyl, —CN, —NO 2 , —N(R u )R v  (wherein R u  and R v  are independently —H or —C 1-6 alkyl), —C(O)N(R u )R v , —N(R u )C(O)R v , —N(R u )SO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —S(O) 0-2 —C 1-6 alkyl, —SO 2 N(R u )R v , —SCF 33  halo, —CF 3 , —OCF 3 , —OCHF 23 —COOH, and —COOC 1-6 alkyl; 
 
 c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has 0, 1, or 2 carbon atoms replaced by —N═, the fused rings optionally mono-, di-, or tri-substituted with R t ; 
 d) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH, or >N(C 1-4 alkyl), having up to one additional carbon atom optionally replaced by —N═, optionally mono- or di-substituted with R t , and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R t ; and 
 e) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N═, optionally mono- or di-substituted with R t , and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R t ; 
 
         and enantiomers, diastereomers, hydrates, solvates thereof, and pharmaceutically acceptable salts, esters, and amides thereof. 
       
     
     
         40 . The compound of  claim 39  wherein R 2  and R 3  are taken together with the nitrogen to which they are attached to form piperidinyl, 4-fluoropiperidinyl, morpholinyl, or 3-methyl morpholin-4-yl. 
     
     
         41 . The compound of  claim 39  wherein Ar 1  is 4-methoxyphenyl or 4-methylsulfanylphenyl. 
     
     
         42 . The compound of  claim 39  wherein R 5  is —H. 
     
     
         43 . A compound selected from the group consisting of:
 Cis-6-(4-methoxy-phenyl)-9-(4-piperidin-1-yl-but-1-ynyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-methoxy-phenyl)-9-(4-piperidin-1-yl-but-1-ynyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-methylsulfanyl-phenyl)-8-(4-piperidin-1-yl-but-1-ynyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Trans-6-(4-methylsulfanyl-phenyl)-8-(4-piperidin-1-yl-but-1-ynyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;   Cis-6-(4-methylsulfanyl-phenyl)-9-(4-piperidin-1-yl-but-1-ynyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline; and   Trans-6-(4-methylsulfanyl-phenyl)-9-(4-piperidin-1-yl-but-1-ynyl)-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline.   
     
     
         44 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one compound of formulae (II) or (III). 
     
     
         45 . A method for the treatment or prevention of a CNS disorder selected from the group consisting of: depression, disturbed sleep, fatigue, lethargy, cognitive impairment, memory impairment, memory loss, learning impairment, and attention-deficit disorders in mammals, comprising the step of administering to a mammal suffering therefrom an effective amount of at least one compound of formulae (II) or (III).